Our Current Trials

Condition	Trial Name	Sponsor
Non-Small Cell Lung Cancer	AdvanTIG-205: Ociperlimab and Tislelizumab as First-Line Treatment in the Metastatic Setting	BeiGene, Ltd.
Non-Small Cell Lung Cancer	AdvanTIG-301: Ociperlimab Plus Tislelizumab Versus Durvalumab After Concomitant Chemo/Radiotherapy	BeiGene, Ltd.
Colon or Rectal Adenocarcinoma	BREAKWATER: First Line Encorafenib + Cetuximab +/- Chemotherapy in Patients Whose Tumors Express a BRAF V600E mutation	Pfizer
Breast Cancer	CDK2/4/6 Inhibitor RGT-419B in HR-Positive, HER2-Negative Metastatic Breast Cancer	Regor Pharmaceuticals, Inc.
Chemotherapy-Induced Oral Mucositis	Chemo Mouthpiece Medical Device Trial	Chemo Mouthpiece, LLC
Prostate Cancer	KPG-121 in Castration Resistant Prostate Cancer	Kangpu Biopharmaceuticals, Ltd.
Colon or Rectal Cancer	KRYSTAL-10: Adagrasib in KRAS G12C Mutated Colorectal Cancer	Mirati Therapeutics, Inc.
Diffuse Large B-Cell Lymphoma	LOTIS-9: Loncastuximab Tesirine and Rituximab (Lonca-R) in Previously Untreated Unfit/Frail Patients	ADC Therapeutics SA
Colon or Rectal Cancer	LUT014 Gel for EGFR-Inhibitor Induced Acneiform Rash	Lutris Pharma Ltd.
Solid Tumors	MyTACTIC: Multiple Cohort Solid Tumor Trial	Genentech, Inc.
Hyperkalemia/Chronic Kidney Disease	NYH-01: Hyperkalemia/Chronic Kidney Disease	Relypsa
Solid Tumors	OnTARGET: Crofelemer for Diarrhea Prophylaxis in Patients Receiving Targeted Therapy	Napo Pharmaceuticals
Acute Myeloid Leukemia, Chronic Myelomonocytic Leukemia, Myelodysplastic Syndrome	PRT1419-03: PRT1419 in Patients with Acute Myeloid Leukemia, Chronic Myelomonocytic Leukemia, or Myelodysplastic Syndrome	Prelude Therapeutics
Oropharyngeal Cancer	VOICE: Clonidine Mucoadhesive Buccal Tablet for Chemoradiotherapy-Induced Oral Mucositis	Monopar Therapeutics Inc.
Non-Small Cell Lung Cancer	ZENITH20: Poziotinib for HER2 Exon 20 Mutated Non-Small Cell Lung Cancer	Spectrum Pharmaceuticals, Inc.
Solid Tumor or Lymphoma	ZL-1201-001: Trial of ZL-1201 in Subjects With Advanced Cancer	Zai Lab (Shanghai) Co., Ltd.
Non-Small Cell Lung Cancer	ZN-e4-001: Zn-e4 in EGFR mutated NSCLC	Zeno Pharmaceuticals, Inc.
Non-Small Cell Lung Cancer, Colorectal Cancer, Melanoma	[Registry] BESPOKE IO: Study of ctDNA Guided Immunotherapy	Natera, Inc.
Muscle-Invasive Bladder Cancer	[Registry] Clinical Performance Evaluation of the C2i-WGS-MRD Test	C2i Genomics Inc.
Prostate Cancer	[Registry] Trial Evaluating the RadTox Assay for Predicting GI Toxicity Associated with Radiation Therapy	DiaCarta, Inc.
Solid Tumors	[Sample Collection] A Prospective Blood Sample Collection Study to Evaluate a Panel of Protein-based Biomarkers (SEERPRO)	Seer, Inc.
Various Indications	[Sample Collection] Clinical Biospecimen Procurement Protocol to Support Advancements in Medical Diagnoses of Diseases (PROMEDx)	Precision for Medicine
Solid Tumors	[Sample Collection] Collection and Distribution of Biofluids for Research Purposes	Bluestar Genomics
Solid Tumors	[Sample Collection] Detecting cancers Earlier Through Elective plasma-based Cancer SEEK Testing (DETECT-ASCEND 2)	Exact Sciences Thrive LLC
Various Indications	[Sample Collection] Discovery and Evaluation of Biomarkers/Pharmacogenomics for the Diagnosis and Personalized Management of Patients (MTG-022)	MT Group
Various Indications	[Sample Collection] Prospective Collection of Samples for Research (SERATRIALS-05035)	SERATRIALS, LLC.
Breast Cancer	persevERA: First Line Treatment with Giredestrant or Letrozole in Combination With Palbociclib in ER-Positive HER2-Negative Advanced/Metastatic Breast Cancer	Hoffmann-La Roche

Our Current Trials

Call Us

COVID-19 - Information